Rapport Therapeutics, Inc.
RAPP Healthcare Biotechnology
In the quarter to June 2026, EPS fell 58.7% and free cash flow fell 64.8%, each against the same quarter a year earlier.
Follow RAPP
Rapport Therapeutics, Inc. (RAPP) Dividend Safety Score
Dividend Safety Score, annual
Annual newest first
| Period | Dividend Safety Score | Change (points) |
|---|
How the score is made up
There are no annual figures to work it out from.
How the stockrow Dividend Safety Score works
Our own composite, out of 100, for the latest fiscal year: up to 25 points for how little of its earnings the dividend takes, 25 for how little of its free cash flow, 20 for net debt against EBITDA, 20 for the years it has paid without a cut and 10 for how steady earnings per share have been over ten years. How we calculate it.
| 80–100 | Well covered |
|---|---|
| 60–79 | Adequately covered |
| 40–59 | Stretched |
| below 40 | Weakly covered |
Not worked out for a company that pays no regular dividend, for banks and REITs, whose payouts and leverage these measures do not describe, or with fewer than five years of earnings.
Dividend Safety Score against peers
| Company | Dividend Safety Score |
|---|---|
| IMCR Immunocore Holdings PLC Sponsored ADR compare | — |
| ANAB AnaptysBio, Inc. compare | — |
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | — |
| ABSI Absci Corporation compare | — |
| OMER Omeros Corporation compare | — |
| ORIC Oric Pharmaceuticals, Inc. compare | — |
| INBX Inhibrx Biosciences, Inc. compare | — |
| RARE Ultragenyx Pharmaceutical Inc. compare | — |
| RAPP Rapport Therapeutics, Inc. | — |
What Dividend Safety Score is
The stockrow Dividend Safety Score rates how well earnings and free cash flow cover the dividend, with leverage, the dividend’s record and stable earnings.
Up to 25 points for the payout of earnings, 25 for the payout of free cash flow, 20 for net debt ÷ EBITDA, 20 for the years without a dividend cut and 10 for stable earnings